SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2021 Jan 14

PMID 33442555

Citations 40

Authors

Adi V Gundlapalli

Reynolds M Salerno

John T Brooks

Francisco Averhoff

Lyle R Petersen

L Clifford McDonald

Michael F Iademarco

Affiliations

Soon will be listed here.

Abstract

Background: There is a need for validated and standardized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quantitative immunoglobulin G (IgG) and neutralization assays that can be used to understand the immunology and pathogenesis of SARS-CoV-2 infection and support the coronavirus disease 2019 (COVID-19) pandemic response.

Methods: Literature searches were conducted to identify English language publications from peer-reviewed journals and preprints from January 2020 through November 6, 2020. Relevant publications were reviewed for mention of IgG or neutralization assays for SARS-CoV-2, or both, and the methods of reporting assay results.

Results: Quantitative SARS-CoV-2 IgG results have been reported from a limited number of studies; most studies used in-house laboratory-developed tests in limited settings, and only two semiquantitative tests have received US Food and Drug Administration (FDA) Emergency Use Authorization (EUA). As of November 6, 2020, there is only one SARS-CoV-2 neutralization assay with FDA EUA. Relatively few studies have attempted correlation of quantitative IgG titers with neutralization results to estimate surrogates of protection. The number of individuals tested is small compared with the magnitude of the pandemic, and persons tested are not representative of disproportionately affected populations. Methods of reporting quantitative results are not standardized to enable comparisons and meta-analyses.

Conclusions: Lack of standardized SARS-CoV-2 quantitative IgG and neutralization assays precludes comparison of results from published studies. Interassay and interlaboratory validation and standardization of assays will support efforts to better understand antibody kinetics and longevity of humoral immune responses postillness, surrogates of immune protection, and vaccine immunogenicity and efficacy. Public-private partnerships could facilitate realization of these advances in the United States and worldwide.

Citing Articles

A Longitudinal Study in Tunisia to Assess the Anti-RBD IgG and IgA Responses Induced by Three Different COVID-19 Vaccine Platforms.

Ben Hamouda W, Hanachi M, Ben Hamouda S, Kammoun Rebai W, Gharbi A, Baccouche A Trop Med Infect Dis. 2024; 9(3).

PMID: 38535885 PMC: 10975151. DOI: 10.3390/tropicalmed9030061.

Quantification of SARS-CoV-2 monoclonal IgG mass fraction by isotope dilution mass spectrometry.

Martos G, Bedu M, Josephs R, Westwood S, Wielgosz R Anal Bioanal Chem. 2024; 416(10):2423-2437.

PMID: 38427100 DOI: 10.1007/s00216-024-05205-z.

Performance of plant-produced RBDs as SARS-CoV-2 diagnostic reagents: a tale of two plant platforms.

Santoni M, Gutierrez-Valdes N, Pivotto D, Zanichelli E, Rosa A, Sobrino-Mengual G Front Plant Sci. 2024; 14:1325162.

PMID: 38239207 PMC: 10794598. DOI: 10.3389/fpls.2023.1325162.

Anti-SARS-CoV-2 Antibody Testing: Role and Indications.

Mink S, Fraunberger P J Clin Med. 2023; 12(24).

PMID: 38137643 PMC: 10744049. DOI: 10.3390/jcm12247575.

Monoclonal Antibodies as SARS-CoV-2 Serology Standards: Experimental Validation and Broader Implications for Correlates of Protection.

Wang L, Patrone P, Kearsley A, Izac J, Gaigalas A, Prostko J Int J Mol Sci. 2023; 24(21).

PMID: 37958688 PMC: 10650176. DOI: 10.3390/ijms242115705.

References

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

Hatchette T, Scholz H, Bolotin S, Crowcroft N, Jackson C, McLachlan E . Calibration and Evaluation of Quantitative Antibody Titers for Measles Virus by Using the BioPlex 2200. Clin Vaccine Immunol. 2016; 24(1). PMC: 5216424. DOI: 10.1128/CVI.00269-16. View

Ripperger T, Uhrlaub J, Watanabe M, Wong R, Castaneda Y, Pizzato H . Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity. 2020; 53(5):925-933.e4. PMC: 7554472. DOI: 10.1016/j.immuni.2020.10.004. View

Wu F, Liu M, Wang A, Lu L, Wang Q, Gu C . Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020; 180(10):1356-1362. PMC: 9377417. DOI: 10.1001/jamainternmed.2020.4616. View

Plotkin S . Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008; 47(3):401-9. DOI: 10.1086/589862. View

Logunov D, Dolzhikova I, Zubkova O, Tukhvatullin A, Shcheblyakov D, Dzharullaeva A . Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396(10255):887-897. PMC: 7471804. DOI: 10.1016/S0140-6736(20)31866-3. View

Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P . Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020; 9(1):940-948. PMC: 7273175. DOI: 10.1080/22221751.2020.1762515. View

Lerner A, Eisinger R, Lowy D, Petersen L, Humes R, Hepburn M . The COVID-19 Serology Studies Workshop: Recommendations and Challenges. Immunity. 2020; 53(1):1-5. PMC: 7309808. DOI: 10.1016/j.immuni.2020.06.012. View

Lei C, Qian K, Li T, Zhang S, Fu W, Ding M . Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun. 2020; 11(1):2070. PMC: 7265355. DOI: 10.1038/s41467-020-16048-4. View

10.

Jackson L, Roberts P, Graham B . A SARS-CoV-2 mRNA Vaccine - Preliminary Report. Reply. N Engl J Med. 2020; 383(12):1191-1192. DOI: 10.1056/NEJMc2026616. View

11.

Bradfute S, Hurwitz I, Yingling A, Ye C, Cheng Q, Noonan T . Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019. J Infect Dis. 2020; 222(10):1620-1628. PMC: 7454720. DOI: 10.1093/infdis/jiaa505. View

12.

Huang A, Garcia-Carreras B, Hitchings M, Yang B, Katzelnick L, Rattigan S . A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020; 11(1):4704. PMC: 7499300. DOI: 10.1038/s41467-020-18450-4. View

13.

Chen J, Subbarao K . The Immunobiology of SARS*. Annu Rev Immunol. 2007; 25:443-72. DOI: 10.1146/annurev.immunol.25.022106.141706. View

14.

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

15.

Juno J, Tan H, Lee W, Reynaldi A, Kelly H, Wragg K . Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020; 26(9):1428-1434. DOI: 10.1038/s41591-020-0995-0. View

16.

Addetia A, Crawford K, Dingens A, Zhu H, Roychoudhury P, Huang M . Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol. 2020; 58(11). PMC: 7587101. DOI: 10.1128/JCM.02107-20. View

17.

Cheng M, Yansouni C, Basta N, Desjardins M, Kanjilal S, Paquette K . Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2 : A Narrative Review. Ann Intern Med. 2020; 173(6):450-460. PMC: 7281623. DOI: 10.7326/M20-2854. View

18.

Long Q, Liu B, Deng H, Wu G, Deng K, Chen Y . Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020; 26(6):845-848. DOI: 10.1038/s41591-020-0897-1. View

19.

GeurtsvanKessel C, Okba N, Igloi Z, Bogers S, Embregts C, Laksono B . An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun. 2020; 11(1):3436. PMC: 7338506. DOI: 10.1038/s41467-020-17317-y. View

20.

Perera R, Mok C, Tsang O, Lv H, Ko R, Wu N . Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020; 25(16). PMC: 7189648. DOI: 10.2807/1560-7917.ES.2020.25.16.2000421. View